Dr. Timothy Stout, recognized leader in gene therapy and eye diseases, has been named chair of ophthalmology at Baylor College of Medicine.
A graduate of Baylor College of Medicine, Stout returns to BCM from Oregon Health and Sciences University (OHSU), where he serves as vice president for commercialization strategies and professor of ophthalmology and molecular genetics.
“With a proven track record and excellent leadership skills, Dr. Tim Stout is the ideal choice to chair the ophthalmology department,” said Dr. Paul E. Klotman, president and CEO of BCM. “He understands Baylor College of Medicine and our strategic vision for the future in patient care, research and education.”
His appointment is effective in December. He will succeed Dr. Dan Jones, who is retiring after serving as chair of ophthalmology at BCM for more than 30 years.
Stout received both his medical degree and doctorate from Baylor College of Medicine.
His mentor in genetics was Dr. Thomas Caskey, the first chair of what is now the Department of Molecular and Human Genetics at BCM.
“I'm very much looking forward to returning home to Baylor and the Cullen Eye Institute,” said Stout. “Danny Jones has set an incredible standard and I look forward to helping shape the future of the department.”
Specializes in retina/macular diseases
He specializes in retina/macular and retinal vascular diseases. His current research projects include human gene and stem cell therapy for proliferative and inherited ocular disease, retinal disease genotype-phenotype correlation and intraocular angiogenesis.
In 2008, Stout was named vice president for commercialization at OHSU with the objective of moving discoveries from the labs to the clinics as rapidly and as safely as possible.
Stout received a bachelor’s of arts degree from Rice University and a master’s of business administration degree from the University of Oregon. He completed his internship at Texas Children’s Hospital and his residency at the University of Southern California after earning his BCM degrees.